Severe CAV MRI in Heart Transplant Recipient

Cardiac Allograft Vasculopathy Clinical Trial

Official title:

Evaluation of Genomic, Structural and Molecular Changes Associated With Severe Cardiac Allograft Vasculopathy in Heart Transplant Recipients

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02777255
• Other study ID #: 1103M96798
• Status: Withdrawn
• Phase: N/A
• First received: March 13, 2013
• Last updated: May 16, 2016
• Start date: May 2012
• Est. completion date: December 2014

Study information

• Verified date: May 2016
• Source: University of Minnesota - Clinical and Translational Science Institute
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Observational

Clinical Trial Summary

Hypothesis: CAV is associated with fibrotic changes on cardiac MRI, altered levels of pathogenetically-related biomarkers, and specific RNA expression changes in the blood

Description:

Cardiac allograft vasculopathy (CAV) is a major limitation to longevity after heart transplantation (HT), accounting for almost 30% of deaths after year 5. The only cure is re-transplant which is associated with a 30-day mortality of 30%, and raises ethical issues due to limited resources. Standard preventive measures, such as statin therapy, have limited success due to the multi-factorial nature of the process and influence of transplant-specific risk factors. Consensus regarding the management of CAV is lacking due to the absence of prospective studies evaluating timing of initiation of therapy, effect of therapies on long-term outcomes, and effective diagnostic strategies. Primary prevention of CAV, which will be evaluated in the proposed study, could improve longevity of heart transplant recipients and optimize use of a limited resource.

The current gold standard for evaluation of CAV is surveillance coronary angiogram, which is highly insensitive, particularly in early disease. Intravascular ultrasound (IVUS) is the most sensitive tool for the diagnosis of CAV, providing specific information such as the appearance and thickness of the intima and media, however it is not widely used in the clinical setting. Physiologic studies of the coronary arteries are also useful in assessing risk, but are not practical in a clinical setting. These invasive studies expose the heart transplant recipient to radiation, nephrotoxic contrast, and potential vascular complications. During the evolution of CAV, there are important structural, functional, and genomic changes that occur in parallel and possibly before.

Study Objectives

1. Determine the structural, functional and genomic changes associated with severe CAV

2. Identify novel and noninvasive markers of CAV

Study Design This is a cross-sectional study which will evaluate structural, functional and genomic changes associated with severe CAV in heart transplant recipients within 15 years of transplant. 30 heart transplant recipients identified via our study database and the transplant clinic will be enrolled into the study. We will enroll 15 heart transplant patients with severe CAV and 15 without CAV.

Subjects will undergo a one-time assessment of radial artery elasticity, blood draw for gene expression profiles, and cardiac MRI.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 2014
• Est. primary completion date: May 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years

• Provide informed consent

• Successful orthotopic heart transplant within 15 years of enrollment

Exclusion Criteria:

• Chronic kidney disease with creatinine >2.5 mg/dl

• Ejection fraction <45% if CAV or <50% if no CAV

• IV contrast allergy or reaction (gadolinium)

• Active infection (febrile illness, cytomegalovirus or other significant infection)

• Treated humoral rejection or cellular rejection grade 3A/2R or greater within 3 months

• Contraindication to MRI

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Cardiac Allograft Vasculopathy
• Vascular Diseases

Locations

Country	Name	City	State
United States	University of Minnesota Medical Center	Minneapolis	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
University of Minnesota - Clinical and Translational Science Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes from baseline associated with severe CAV	Determine the structural (degree of fibrosis), functional and genomic changes associated with severe CAV	1 year	No
Secondary	Novel noninvasive markers of CAV from baseline	Identify novel and noninvasive markers of CAV	1 year	No